A 3D-printed hollow microneedle (HMN) platform using digital light processing (DLP) fabrication successfully delivered resveratrol-loaded PLGA nanoparticles (RSV-NPs) into human skin at two distinct depths: 1 mm needles reached the dermis, while 1.5 mm needles penetrated the dermis-hypodermis interface. RSV-NPs demonstrated high encapsulation efficiency, sustained release kinetics, UV photoprotection, and maintained antioxidant activity with favorable biocompatibility confirmed in human volunteer skin compatibility trials.
Topical antioxidant delivery has long been stymied by the stratum corneum — a formidable 10–20 µm barrier that degrades or blocks most bioactive compounds before meaningful tissue concentrations are achieved. Resveratrol, despite robust in vitro evidence for antioxidant, anti-inflammatory, and potential anti-aging effects, has notoriously poor skin bioavailability in conventional formulations. This platform elegantly addresses three simultaneous challenges: physical barrier bypass via microneedles, compound stabilization via PLGA nanoencapsulation, and depth-programmable delivery through tunable needle geometry.
The practical implications are meaningful — a patient-administered device could replicate outcomes currently requiring clinical microneedling sessions. However, significant caveats remain. The study is explicitly preclinical and proof-of-concept; efficacy endpoints (measurable antioxidant activity in dermis, clinical skin outcomes) were not assessed. Human data is limited to tolerability only. Scale-up manufacturing consistency and long-term device stability under real-world conditions are unproven. Incremental rather than paradigm-shifting, this work nonetheless represents a technically credible convergence of microfabrication and nanomedicine for accessible cosmeceutical delivery.
